Pharma Update

Building blocks for future growth through 2030 4 NMEs in oncology with FIC/BIC potential in late stage development Oncology/Hematology Neuroscience Ophthalmology Immunology CVM Emerging assets from early pipeline and BD anti-IL6 mAb ASO Factor B zilebesiran SPK-8011 tobemstomig Roche trontinemab anti-latent myostatin mAb Susvimo Gazyva astegolimab Susvimo Gazyva astegolimab divarasib Elevidys Enspryng fenebrutinib divarisib Elevidys Enspryng fenebrutinib crovalimab tiragolumab inavolisib giredestrant crovalimab tiragolumab inavolisib giredestrant Vabysmo Ocrevus Evrysdi Vabysmo Ocrevus Evrysdi Vabysmo Ocrevus Evrysdi Hemlibra Tecentriq Venclexta Alecensa Hemlibra Tecentriq Venclexta Alecensa Hemlibra Tecentriq Venclexta Alecensa Phesgo Columvi Lunsumio Polivy Phesgo Columvi Lunsumio Polivy Phesgo Columvi Lunsumio Polivy Launched portfolio Mid-term opportunities* Long-term opportunities** CVM = cardiovascular / metabolism; *mid-term defined as filing 2024-2026, **long-term defined as filing after 2026, BD-business development 71

View entire presentation